Compass Therapeutics (CMPX) Non-cash Items (2020 - 2026)

Compass Therapeutics has disclosed Non-cash Items across 7 years of filings, most recently posting $32.5 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $32.5 million, up 51.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.5 million (up 51.04% YoY), and the FY2025 annual result was $36.6 million, up 6223.66% from the prior year.
• Non-cash Items came in at $32.5 million for Q1 2026 at Compass Therapeutics, down from $36.6 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $36.6 million in Q4 2025 to a low of $11000.0 in Q4 2023.
• The 5-year median for Non-cash Items is $9.8 million (2022), against an average of $11.4 million.
• Across the five-year window, Non-cash Items slumped 99.83% in 2023 and soared 6223.66% in 2025, its largest moves.
• Compass Therapeutics' Non-cash Items stood at $6.3 million in 2022, then plunged by 99.83% to $11000.0 in 2023, then surged by 5163.64% to $579000.0 in 2024, then jumped by 6223.66% to $36.6 million in 2025, then retreated by 11.31% to $32.5 million in 2026.
• The last three Non-cash Items figures came in at $32.5 million (Q1 2026), $36.6 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.